UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2024

COMMISSION FILE NUMBER 001-38455

MorphoSys AG

Semmelweisstrasse 7

82152 Planegg

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On August 29, 2024, MorphoSys AG (the “Company”) published the half-year report January – June 2024 attached hereto as Exhibit 99.1.

Exhibit 99.1 to this report on Form 6-K is incorporated by reference, other than the information under the Sections “Proprietary Clinical Development” on pages 7-9 and “Financial Guidance” on page 17-18, in the registration statement on Form S-8 (File No. 333-277693) of MorphoSys AG and in the outstanding prospectus contained in such registration statement.

Exhibits

99.1 Half -Year Report January – June 202 4

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MORPHOSYS AG (Registrant)

Date: August 29, 2024 By: /s/ i.A. Isabelle Degbegni

Name: Isabelle Degbegni

Title: Director Investor Relations

By: /s/ i.A. Dr. Robert Mayer

Name: Dr. Robert Mayer

Title: Director Investor Relations

MorphoSys AG 6-K